SCHEMBL2977016

SCHEMBL2977016

CCCNC(=O)c1ccc(C(N)=O)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.65
KMT2A Q03164 1/20 0.65
NAMPT P43490 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.53
EPHX2 P34913 1/20 0.53
NR1H4 Q96RI1 1/20 0.53
ALDH1A1 P00352 3/20 0.50
LMNA P02545 3/20 0.50
TSHR P16473 2/20 0.50
NAAA Q02083 1/20 0.50
SLC22A2 O15244 1/20 0.50
SLC22A1 O15245 1/20 0.50
ACHE P22303 1/20 0.50
MAPK1 P28482 1/20 0.50
CYP2C19 P33261 1/20 0.50
DRD2 P14416 1/20 0.50
DRD4 P21917 1/20 0.50
DRD3 P35462 1/20 0.50
CA2 P00918 1/20 0.50
CHRNA10 Q9GZZ6 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13918749 0.90 KDM4E (0.70) KDM4EKMT2ANAMPTL3MBTL1ALDH1A1
SCHEMBL2967223 0.89 L3MBTL1 (0.63) KDM4EKMT2AL3MBTL1EPHX2ALDH1A1
SCHEMBL15168443 0.88 LMNA (0.55) KDM4EKMT2AEPHX2NR1H4ALDH1A1
SCHEMBL5072880 0.87 L3MBTL1 (0.71) KDM4EKMT2AL3MBTL1ALDH1A1NAAA
SCHEMBL28758082 0.86 L3MBTL1 (0.73) KMT2AL3MBTL1ALDH1A1NAAAMAPK1
SCHEMBL19455890 0.86 L3MBTL1 (0.73) KMT2AL3MBTL1ALDH1A1NAAAMAPK1
SCHEMBL28327476 0.86 L3MBTL1 (0.73) KMT2AL3MBTL1ALDH1A1NAAAMAPK1
SCHEMBL11220824 0.86 L3MBTL1 (0.73) KMT2AL3MBTL1ALDH1A1NAAAMAPK1
SCHEMBL11224030 0.86 L3MBTL1 (0.73) KMT2AL3MBTL1ALDH1A1NAAAMAPK1
SCHEMBL27699888 0.86 L3MBTL1 (0.73) KMT2AL3MBTL1ALDH1A1NAAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3864119-A1 LIQUID COMPOSITION WITH DIHYDROXYTEREPHTHALIC ACID DIAMIDE COMPOUND WITH A HIGH SURFACTANT QUANTITY Henkel AG & Co. KGaA (DE) 2021-08-18 EP disclosed
US-7776847-B2 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2010-08-17 US disclosed
US-20060229294-A1 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2006-10-12 US disclosed
WO-2002024635-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229294-A1 Benzisothiazoles useful for treating or preventing HCV infection HAVCR2, ZC3HAV1, MAVS KDM4E 2196/4885KMT2A 2900/4885NAMPT 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.